RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin

Zhang, Shuhui; Zhou, Lin; Zhang, Mengdi; Wang, Yuehua; Wang, Mengqi; Du, Jincheng; Gu, Wenwen; Kui, Fuguang; Li, Jiahuan; Geng, Shengnan; Du, Gangjun

doi:10.3389/fphar.2019.01658

Cited by 36 publications

(24 citation statements)

References 58 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Long term treatment of DOX can induce MDR by transforming N1 into N2 neutrophil phenotypes via upregulation of CD133, CD309, and PD-L1 expression in HL-60 cells. Treatment using the combination of berberine and DOX can maintain the N1 neutrophil polarization and stimulate immune checkpoints to reverse MDR by downregulating CD133, CD309, PD-1, and PD-L1 expression in HCC allograft model ( Zhang et al, 2019 ).…”

Section: Combination Therapymentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer is a serious disease with an increasing number of reported cases and high mortality worldwide. Gastrointestinal cancer defines a group of cancers in the digestive system, e.g., liver cancer, colorectal cancer, and gastric cancer. Coptidis Rhizoma (C. Rhizoma; Huanglian, in Chinese) is a classical Chinese medicinal botanical drug for the treatment of gastrointestinal disorders and has been shown to have a wide variety of pharmacological activity, including antifungal, antivirus, anticancer, antidiabetic, hypoglycemic, and cardioprotective effects. Recent studies on C. Rhizoma present significant progress on its anticancer effects and the corresponding mechanisms as well as its clinical applications. Herein, keywords related to C. Rhizoma, cancer, gastrointestinal cancer, and omics were searched in PubMed and the Web of Science databases, and more than three hundred recent publications were reviewed and discussed. C. Rhizoma extract along with its main components, berberine, palmatine, coptisine, magnoflorine, jatrorrhizine, epiberberine, oxyepiberberine, oxyberberine, dihydroberberine, columbamine, limonin, and derivatives, are reviewed. We describe novel and classic anticancer mechanisms from various perspectives of pharmacology, pharmaceutical chemistry, and pharmaceutics. Researchers have transformed the chemical structures and drug delivery systems of these components to obtain better efficacy and bioavailability of C. Rhizoma. Furthermore, C. Rhizoma in combination with other drugs and their clinical application are also summarized. Taken together, C. Rhizoma has broad prospects as a potential adjuvant candidate against cancers, making it reasonable to conduct additional preclinical studies and clinical trials in gastrointestinal cancer in the future.

show abstract

Section: Combination Therapymentioning

confidence: 99%

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Chen

Liang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The protein-protein interaction (PPI) among these potential targets was constructed using the STRING database ( ) ( Du et al, 2019 ). The compound-target-pathway network was constructed using Cytoscape 3.7.2 ( Zhang et al, 2019 ).…”

Section: Methodsmentioning

confidence: 99%

Jian-Pi-Bu-Xue-Formula Alleviates Cyclophosphamide-Induced Myelosuppression via Up-Regulating NRF2/HO1/NQO1 Signaling

Huang

Feng

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Jian-pi-bu-xue-formula (JPBXF), a TCM formula composed of twelve Chinese medicinal herbs, has been used in clinic to ease patients' state of weakness and fatigue especially after receiving anti-tumor chemotherapy in China. The lack of the phytochemical characterization, detail therapeutic evaluation and mechanism of JPBXF remains the main limitation for its spreading. In this study, we systematically evaluated the effectiveness and underline mechanism of JPBXF on cyclophosphamide (CTX)-induced myelosuppression and identified the main constituents of JPBXF aqueous extract. JPBXF treatments reversed CTX-induced myelosuppression through increasing the number of haematopoietic stem cells (HSCs) and expression of C-kit in bone marrow cells. Simultaneously, JPBXF treatments alleviated CTX-induced blood cells reduction by increasing numbers of RBCs and WBCs and levels of GM-CSF, TPO and EPO in plasma. JPBXF treatments reduced CTX-induced immunosuppression by increasing expressions of CD3, CD4, and CD8a in PBMCs, and recovering structure damages of thymus and spleen. Moreover, JPBXF notably increased the expression of NRF2 compared with CTX group, and subsequently up-regulated HO1 and NQO1 both in mRNA and protein levels. In addition, eighteen compounds were recognized from JPBXF aqueous extract and the potential targets of the identified compounds were predicted. Overall, JPBXF can greatly reverse CTX-induced myelosuppression in C57BL/6 mice, especially in improving the blood and immune function through activating NRF2/HO1/ NQO1 signaling pathway, which provides a reliable reference for JPBXF application in clinical. By recognizing eighteen compounds in JPBXF aqueous extract and predicting the underline mechanisms of the identified compounds, our study would provide theoretical guidance for further research of JPBXF.

show abstract

“…When HL-60 cells were cultured to a concentration of 5×10 5 cells/mL, they were rst cultured with 1uM all-trans retinoic acid (ATRA) medium, and the medium was exchanged with 1uM ATRA medium on the third day, and the cells obtained from culture to the fth day which were recorded as N1-HL-60. On the 5th day, the cells were obtained by culturing for 24 hours with 50ng/mL TGF-β which were designated as N2-HL-60 [19,20]. The cells were collected on the 6th day, and the N1-HL-60 and N2-HL-60 were separated by CD66b antibody ow cytometry analysis.…”

Section: Cell Culturementioning

confidence: 99%

“…Therefore, we explored whether there is a difference in the polarity of neutrophils. Referring to previous articles [21,19], we used CD206 to label polarized N2 neutrophils in mice. Mice were divided into sham, I/R+control IgG, I/R+LCN2mAb groups.…”

Section: Lcn2mab Affects Neutrophils To N2-type Polarizationmentioning

confidence: 99%

Lipocalin-2 Mediated Polarization of Neutrophil in Cerebral Ischemia-Reperfusion Injury

Guo

Guo-li

et al. 2021

Preprint

View full text Add to dashboard Cite

Cerebral ischemia-reperfusion (I/R) injury is a difficult point in the treatment of ischemic stroke. Lipocalin-2 (LCN2) and neutrophils play an important role in I/R injury. We explored the effect of anti-LCN2 antibody (LCN2mAb) and to further clarify the relationship between LCN2mAb and neutrophil polarization (N1/N2 neutrophils) in I/R injury. A mouse middle cerebral artery occlusion (MCAO) model was used to induce transient cerebral ischemia. LCN2mAb was administered 1h before MCAO; Anti-Ly6G was administered for 3d before MCAO. The expression of LCN2 and Ly6G was Measured by western blot. Infarct size,behavior and the blood-brain barrier (BBB) damage were assessed. The polarized N2 neutrophils were measured by western blot and Flow Cytometry. Using HL-60 as a cell model explores the role of LCN2mAb in the polarity transition of neutrophils. The expression of LCN2 and Ly6G in the brain at different time points reached a peak after I/R 24h and then gradually decreased. As demonstrated previously, LCN2mAb-treated mice had neuroprotective effects in cerebral infarction volume, behavior, and blood-brain barrier damage. The expression of Ly6G was not significantly different, but the expression of N2 neutrophils was increased. The expression of anti-inflammatory factor CD206 was significantly increased, and pro-inflammatory factor TNF-α was significantly reduced. Compared with mice treated with Anti-Ly6G, Anti-Ly6G-LCN2mAb combined treatment of I/R, there was no further improvement in behavior and pathology. Based on HL-60 as a cell model, N1-HL-60 cells were pretreated with LCN2mAb, and N2-HL-60 cells were significantly increased. LCN2 may affect the prognosis of ischemic stroke by mediating neutrophils polarization.

show abstract

RETRACTED: Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin

Cited by 36 publications

References 58 publications

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers

Jian-Pi-Bu-Xue-Formula Alleviates Cyclophosphamide-Induced Myelosuppression via Up-Regulating NRF2/HO1/NQO1 Signaling

Lipocalin-2 Mediated Polarization of Neutrophil in Cerebral Ischemia-Reperfusion Injury

Contact Info

Product

Resources

About